In conclusion, for the first time, our findings validated DCN's cardioprotective potency against DIC based on its antioxidant, anti-inflammatory, anti-ferroptotic, and anti-apoptotic imprint, chiefly mediated by the NRF2/SLC7A11/GPX4 axis. Accordingly, DCN could represent a promising therapeutic avenue for patients under DOX-dependent chemotherapy.

P2, N=210, Recruiting, Shaperon | Not yet recruiting --> Recruiting

Mechanistically, the suppression of p-STAT3 expression following DCLK1 inhibition by diacerein or specific DCLK1 siRNA was observed. Furthermore, diacerein effectively disrupted the DCLK1/STAT3 signaling pathway and its downstream targets, including MCL-1, VEGF, and survivin, thereby inhibiting CRC progression in a mouse model, thereby inhibiting CRC progression in a mouse model.

P2, N=24, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=138 --> 24

P2, N=34, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Terminated by sponsor

P=N/A, N=100, Recruiting, Nanjing University School of Medicine

P2, N=53, Completed, Celgene | Trial primary completion date: Nov 2018 --> Sep 2023

P2/3, N=230, Recruiting, MediciNova | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

This interim analysis showed a good maintenance of canakinumab treatment 2 years after initiation and confirmed its safety profile in real-life practice in France in patients diagnosed with FMF, MKD and TRAPS. The high variety of dose and interval combinations observed in canakinumab treated patients let suppose that physicians adapt the posology to individual situations rather than a fixed treatment plan.

P2, N=150, Recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024

P2, N=200, Recruiting, AbbVie | Initiation date: Oct 2024 --> Mar 2024

P2, N=66, Not yet recruiting, ReAlta Life Sciences, Inc.

P2, N=200, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Oct 2024

P2/3, N=230, Recruiting, MediciNova | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=50, Active, not recruiting, MediciNova | Phase classification: P1b/2a --> P1/2

P1, N=50, Completed, AbbVie | Active, not recruiting --> Completed

Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved survival outcomes. Here, we discuss AEs associated with pomalidomide and present five clinically relevant hypothetical case studies in patients with RRMM to provide scenario-driven guidance regarding treatment selection and AE prevention and management in the clinical setting. Lastly, as new treatment approaches continue to be explored in MM, we also discuss novel cereblon E3 ligase modulator (CELMoD™) agents including iberdomide (CC-220) and mezigdomide (CC-92480).

P2, N=29, Active, not recruiting, Emory University | Trial completion date: Aug 2024 --> Mar 2026 | Trial primary completion date: Jul 2024 --> Mar 2025

Based on the cocultures, adding pomalidomide significantly promoted IFN-γ and TNF-α secretion (P < .05). Based on the above clinical and in vitro studies demonstrating the co-administration of pomalidomide with CAR-T cell treatment demonstrated favorable tolerability and therapeutic effectiveness in RRMM or B-cell leukemia/lymphoma.

Overproduction of pro-inflammatory cytokines and the hyperactivation of NOD2-mediated signaling pathways were found in the NOD2 variant Q902K patient with YAOS. NOD2-RIP2-MAPK pathway might play a pivotal role in the pathogenesis of YAOS. These results provide new perspectives for targeted therapies in YAOS.

P2, N=150, Not yet recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

P1/2, N=56, Active, not recruiting, Cristina Gasparetto | Trial completion date: Jan 2023 --> Jan 2025

Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS.

P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=190 --> 17

P2, N=54, Active, not recruiting, Amgen | Trial completion date: Dec 2025 --> Oct 2024

P1/2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1b/2 --> P1/2

P2, N=200, Not yet recruiting, AbbVie

P2, N=43, Recruiting, Shanxi Bethune Hospital

Adding canakinumab to docetaxel did not provide additional benefit for patients with advanced NSCLC who had progressed after PDC and immunotherapy.

P2/3, N=80, Recruiting, TWi Biotechnology, Inc. | Not yet recruiting --> Recruiting

No abstract available

However, the variations in CRP levels, that depend on sex, ethnicity, hormonal status, and some peculiarities of the measurement assays, must be taken into consideration when deciding to implement CRP as a useful biomarker in the study and treatment of atherosclerotic cardiovascular disease. This review aims to offer an updated vision of the importance of measuring CRP levels as a biomarker of cardiovascular risk beyond the traditional factors that estimate the risk of atherosclerotic disease.

These findings suggest CU06-1004 as a potential therapeutic agent for folic acid-induced AKI.

P1, N=56, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=99 --> 56

This study provides one of the largest epidemiologic datasets for CAPS. While early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS following canakinumab treatment.

P2, N=138, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2025 --> Jun 2024 | Trial primary completion date: Oct 2025 --> Jun 2024

Cholesterol-inflammation lowering agents (statins), monoclonal antibodies targeting IL-1 and IL-6 (canakinumab and tocilizumab), disease-modifying antirheumatic drugs (methotrexate), sodium-glucose transport protein-2 (SGLT2) inhibitors, colchicine and xanthene oxidase inhibitor (allopurinol) have shown promising results in reducing inflammation, regressing atherogenic plaque and modifying the course of CAD. Here, we review the complex interplay between inflammatory, endothelial, smooth muscle and foam cells. Moreover, the putative role of inflammation in atherosclerotic CAD, underlying mechanisms and potential therapeutic implications are also discussed herein.

However, antioxidant parameters such as reduced glutathione (GSH) and total antioxidant capacity (TAC) significantly declined. Fortunately, DIA reversed the diabetic cardiomyopathy changes mostly due to the observed anti-inflammatory, antioxidant, and anti-apoptotic properties with regulation of blood glucose level.DIA has an ability to regulate DCM-associated biochemical and histopathological disturbances.

In orthotopic and lung metastatic breast cancer models, FTF-BL-CP produced notable therapeutic benefits of retarding tumor growth, extending survivals, and inhibiting lung metastasis. Therefore, this ECM-trapping strategy provides an encouraging possibility of prolonging tumor retention to potentiate the antitumor immunity for anticancer immunotherapy.

P2, N=190, Recruiting, Mayo Clinic | Trial primary completion date: Mar 2024 --> Nov 2024

P2, N=24, Recruiting, ReAlta Life Sciences, Inc. | Not yet recruiting --> Recruiting